Tempus ECG-Low EF vs ElucidVivo A.3
AI Verdict
Choose Tempus ECG-Low EF if…
Choose Tempus ECG-Low EF if your primary goal is to quickly screen and identify patients aged 40 or older who may be at risk for heart failure, using readily available 12-lead ECG data. This tool is ideal for initial assessments in settings like emergency departments or primary care where a rapid, non-invasive indicator of low LVEF can prompt further diagnostic evaluation.
View Tempus ECG-Low EF →Choose ElucidVivo A.3 if…
Choose ElucidVivo A.3 if you require detailed, quantitative analysis of arterial plaque composition and stability from CT angiography to refine atherosclerosis patient stratification and treatment planning. This system is best suited for specialists like interventional cardiologists or vascular surgeons who need to precisely visualize and measure plaque characteristics, including lipid-rich necrotic core and calcifications, to optimize therapeutic decisions.
View ElucidVivo A.3 →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-Low EF | ElucidVivo A.3 |
|---|---|---|
| Deployment | Integrates with current ECG platforms and electronic health records (EHRs). | Cloud and on-premise secure deployment. |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Tempus ECG-Low EFTempus ECG-Low EF (Tool A) operates without a dedicated user interface, integrating seamlessly into existing healthcare facility workflows and providing a simple binary output. This backend integration minimizes direct user interaction and training, making it highly usable for broad clinical application. ElucidVivo A.3 (Tool B), while offering rich visualization, requires more specialized interaction with its imaging analysis software.
Clinical Value
ElucidVivo A.3ElucidVivo A.3 (Tool B) provides a more profound and predictive clinical insight through its quantitative analysis of arterial plaque composition and stability, validated against ground-truth histology, and its ability to derive fractional flow reserve (FFRct). This offers a higher level of diagnostic precision for atherosclerosis patient stratification and treatment optimization. Tempus ECG-Low EF (Tool A) offers valuable early detection of low LVEF with good sensitivity and specificity, but its binary output is a screening aid rather than a comprehensive diagnostic tool.
Pricing & Value
ElucidVivo A.3While both tools require direct vendor contact for pricing, ElucidVivo A.3 (Tool B) has publicly announced broad reimbursement and coverage by major insurers like United Healthcare for its plaque analysis. This significantly enhances its value proposition and accessibility for healthcare providers. Tempus ECG-Low EF (Tool A) has CPT codes for algorithmic ECG assessments, indicating a pathway for reimbursement, but lacks explicit broad coverage announcements.
Enterprise Readiness
Tempus ECG-Low EFTempus ECG-Low EF (Tool A) explicitly states it is HIPAA compliant and offers a Business Associate Agreement (BAA), which are critical assurances for enterprise adoption and legal compliance in healthcare. While ElucidVivo A.3 (Tool B) implies HIPAA compliance due to its FDA clearance and intended use, these crucial details are not explicitly stated in its specifications.
Innovation
ElucidVivo A.3ElucidVivo A.3 (Tool B) demonstrates greater innovation by offering the first and only FDA-cleared, non-invasive plaque analysis based on objective histology, providing unique quantitative insights into arterial plaque composition and stability. Its ability to derive FFRct from CT angiography further enhances its novel approach to personalized atherosclerosis management. Tempus ECG-Low EF (Tool A) is innovative in applying AI to ECGs for LVEF detection, but Tool B's histological validation and FFRct derivation represent a more advanced diagnostic capability.
Support & Docs
Tempus ECG-Low EFTempus AI (Tool A) provides more explicit and detailed information regarding its customer support channels, including dedicated phone numbers, email addresses, and specified operating hours for assistance. Elucid Bioimaging (Tool B) offers general contact information but lacks comparable specific details about its product support resources or documentation.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-Low EF | ElucidVivo A.3 |
|---|---|---|
| Name | Tempus ECG-Low EF | ElucidVivo A.3 |
| Company | Tempus AI | Elucid Bioimaging |
| Primary Function/Key Analysis | AI software analyzing 12-lead ECGs to detect signs of low LVEF (u226440%) in patients 40+ at risk of heart failure. | AI-powered medical image analysis system for quantitative analysis of arterial plaque composition and stability from CT angiography. |
| Input Data Type | 12-lead ECG recordings (resting, non-ambulatory) | CT angiography images |
| Output Type | Binary output (Low LVEF Detected / Not Detected) | Detailed visualization and measurement of plaque characteristics, 3D visualization, rotatable curved MPR vessel views and cross-sections, fractional flow reserve (FFRct) derivation. |
| Target Patient Population/Condition | Patients 40+ years at risk of heart failure (specifically low LVEF u226440%) | Patients with atherosclerosis (for stratification and treatment decisions) |
| Specialties | Cardiology, Emergency Medicine, Internal Medicine | Cardiology, Radiology, Vascular Surgery |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-Low EF and ElucidVivo A.3.
Frequently Asked Questions
More Comparisons
More matchups featuring Tempus ECG-Low EF or ElucidVivo A.3
Backers
Who funded each tool's parent company.